Matthias Kometer
Neuroscientist and Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Matthias Kometer appears in 18 tracked papers (2010–2025), most studied alongside Psilocybin, Ayahuasca and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Schizophrenia.
Most-cited paper: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders (706 citations).
Frequent co-authors: Franz Vollenweider, Milan Scheidegger and Erich Seifritz.
Publication Landscape
How the 18 papers Blossom tracks for Matthias Kometer line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Matthias Kometer's publishing grown?
SourcedTracked papers by publication year; 2 earlier papers published before 2011. Click a year for the running total.
Don't read as total output: only the 18 of 18 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Matthias Kometer publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Matthias Kometer publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Matthias Kometer is a neuroscientist and clinical researcher known for a body of work that combines psychopharmacology, neuroimaging (fMRI/EEG) and cognitive neuroscience to study the effects of serotonergic psychedelics in humans. Working within clinical research groups that include the Vollenweider lab at the University of Zurich, Kometer has contributed key empirical studies and reviews that map the pharmacological, neural and psychological mechanisms of compounds such as psilocybin, DMT/ayahuasca-inspired formulations and classical hallucinogens. His research spans acute neural responses (including P300 and other event-related potentials), changes in default mode network connectivity, and behavioural outcomes such as empathy, moral decision-making and self–other processing.
Key Impact
Notable for pioneering human neuroimaging and psychopharmacological research that has elucidated how serotonergic psychedelics alter self-processing, affect and social cognition, and for translating these findings toward psychiatric applications.
Collaboration Network
22 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Matthias Kometer's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.